Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
CONTEXT: Somatotroph adenomas harboring aryl hydrocarbon receptor interacting protein (AIP) mutations respond less well to somatostatin analogs, suggesting that the effects of somatostatin analogs may be mediated by AIP. OBJECTIVE: The objective of the investigation was to study the involvement of...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1797052294711214080 |
|---|---|
| author | Chahal, H Trivellin, G Leontiou, C Alband, N Fowkes, R Tahir, A Igreja, S Chapple, J Jordan, S Lupp, A Schulz, S Ansorge, O Karavitaki, N Carlsen, E Wass, J Grossman, AB Korbonits, M |
| author_facet | Chahal, H Trivellin, G Leontiou, C Alband, N Fowkes, R Tahir, A Igreja, S Chapple, J Jordan, S Lupp, A Schulz, S Ansorge, O Karavitaki, N Carlsen, E Wass, J Grossman, AB Korbonits, M |
| author_sort | Chahal, H |
| collection | OXFORD |
| description | CONTEXT: Somatotroph adenomas harboring aryl hydrocarbon receptor interacting protein (AIP) mutations respond less well to somatostatin analogs, suggesting that the effects of somatostatin analogs may be mediated by AIP. OBJECTIVE: The objective of the investigation was to study the involvement of AIP in the mechanism of effect of somatostatin analogs. DESIGN: In the human study, a 16-wk somatostatin analog pretreatment compared with no pretreatment. In the in vitro cell line study, the effect of somatostatin analog treatment or small interfering RNA (siRNA)/plasmid transfection were studied. SETTING: The study was conducted at a university hospital. PATIENTS: Thirty-nine sporadic and 10 familial acromegaly patients participated in the study. INTERVENTION: Interventions included preoperative lanreotide treatment and pituitary surgery. OUTCOME: For the human study, GH and IGF-I levels, AIP, and somatostatin receptor staining were measured. For the cell line, AIP and ZAC1 (zinc finger regulator of apoptosis and cell cycle arrest) expression, metabolic activity, and clone formation were measured. RESULTS: Lanreotide pretreatment reduced GH and IGF-I levels and tumor volume (all P < 0.0001). AIP immunostaining was stronger in the lanreotide-pretreated group vs. the surgery-only group (P < 0.001). After lanreotide pretreatment, the AIP score correlated to IGF-I changes in females (R = 0.68, P < 0.05). Somatostatin receptor staining was not reduced in samples with AIP mutations. In GH3 cells, 1 nm octreotide increased AIP mRNA and protein (both P < 0.01) and ZAC1 mRNA expression (P < 0.05). Overexpression of wild-type (but not mutant) AIP increased ZAC1 mRNA expression, whereas AIP siRNA knockdown reduced ZAC1 mRNA (both P < 0.05). The siRNA-mediated knockdown of AIP led to an increased metabolic activity and clonogenic ability of GH3 cells compared with cells transfected with a nontargeting control (both P < 0.001). CONCLUSION: These results suggest that AIP may play a role in the mechanism of action of somatostatin analogs via ZAC1 in sporadic somatotroph tumors and may explain their lack of effectiveness in patients with AIP mutations. |
| first_indexed | 2024-03-06T18:30:16Z |
| format | Journal article |
| id | oxford-uuid:096513c7-fe5c-403d-ba90-878165240c2d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:30:16Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:096513c7-fe5c-403d-ba90-878165240c2d2022-03-26T09:18:11ZSomatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:096513c7-fe5c-403d-ba90-878165240c2dEnglishSymplectic Elements at Oxford2012Chahal, HTrivellin, GLeontiou, CAlband, NFowkes, RTahir, AIgreja, SChapple, JJordan, SLupp, ASchulz, SAnsorge, OKaravitaki, NCarlsen, EWass, JGrossman, ABKorbonits, M CONTEXT: Somatotroph adenomas harboring aryl hydrocarbon receptor interacting protein (AIP) mutations respond less well to somatostatin analogs, suggesting that the effects of somatostatin analogs may be mediated by AIP. OBJECTIVE: The objective of the investigation was to study the involvement of AIP in the mechanism of effect of somatostatin analogs. DESIGN: In the human study, a 16-wk somatostatin analog pretreatment compared with no pretreatment. In the in vitro cell line study, the effect of somatostatin analog treatment or small interfering RNA (siRNA)/plasmid transfection were studied. SETTING: The study was conducted at a university hospital. PATIENTS: Thirty-nine sporadic and 10 familial acromegaly patients participated in the study. INTERVENTION: Interventions included preoperative lanreotide treatment and pituitary surgery. OUTCOME: For the human study, GH and IGF-I levels, AIP, and somatostatin receptor staining were measured. For the cell line, AIP and ZAC1 (zinc finger regulator of apoptosis and cell cycle arrest) expression, metabolic activity, and clone formation were measured. RESULTS: Lanreotide pretreatment reduced GH and IGF-I levels and tumor volume (all P < 0.0001). AIP immunostaining was stronger in the lanreotide-pretreated group vs. the surgery-only group (P < 0.001). After lanreotide pretreatment, the AIP score correlated to IGF-I changes in females (R = 0.68, P < 0.05). Somatostatin receptor staining was not reduced in samples with AIP mutations. In GH3 cells, 1 nm octreotide increased AIP mRNA and protein (both P < 0.01) and ZAC1 mRNA expression (P < 0.05). Overexpression of wild-type (but not mutant) AIP increased ZAC1 mRNA expression, whereas AIP siRNA knockdown reduced ZAC1 mRNA (both P < 0.05). The siRNA-mediated knockdown of AIP led to an increased metabolic activity and clonogenic ability of GH3 cells compared with cells transfected with a nontargeting control (both P < 0.001). CONCLUSION: These results suggest that AIP may play a role in the mechanism of action of somatostatin analogs via ZAC1 in sporadic somatotroph tumors and may explain their lack of effectiveness in patients with AIP mutations. |
| spellingShingle | Chahal, H Trivellin, G Leontiou, C Alband, N Fowkes, R Tahir, A Igreja, S Chapple, J Jordan, S Lupp, A Schulz, S Ansorge, O Karavitaki, N Carlsen, E Wass, J Grossman, AB Korbonits, M Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. |
| title | Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. |
| title_full | Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. |
| title_fullStr | Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. |
| title_full_unstemmed | Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. |
| title_short | Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. |
| title_sort | somatostatin analogs modulate aip in somatotroph adenomas the role of the zac1 pathway |
| work_keys_str_mv | AT chahalh somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT trivelling somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT leontiouc somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT albandn somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT fowkesr somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT tahira somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT igrejas somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT chapplej somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT jordans somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT luppa somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT schulzs somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT ansorgeo somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT karavitakin somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT carlsene somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT wassj somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT grossmanab somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway AT korbonitsm somatostatinanalogsmodulateaipinsomatotrophadenomastheroleofthezac1pathway |